Dublin, July 13, 2022 (GLOBE NEWSWIRE) -- The "Global Hematologic Malignancies Testing Market: Focus on Hematologic Malignancies Testing Product and Application, Supply Chain Analysis, and Country Analysis - Analysis and Forecast, 2022-2032" report has been added to ResearchAndMarkets.com's offering.
Hematologic Malignancies Testing Market: Industry Overview
The global hematologic malignancies testing market is projected to reach $11,680.1 million by 2032, growing from $2,606.5 million in 2021, at a CAGR of 14.23% during the forecast period 2022-2032. The global market for hematologic malignancies testing has grown significantly, owing to the rising demand for numerous biomarker-based molecular diagnostics.
The advancements have aided in enhancing the quality of life and decreasing treatment costs and time, driving the overall growth of the healthcare diagnostics market. Furthermore, the worldwide hematologic malignancies testing market is being driven by rising awareness and adoption of the precision diagnostic technique in both developed and developing countries.
Market Lifecycle Stage
Hematologic malignancies are a type of cancer that starts in blood-forming tissue, such as the bone marrow or immune system cells. With an enhanced genomic review of cancer and developments in molecular diagnostic technology, genetic characterization has become increasingly important in the clinical evaluation of practically every kind of hematologic malignancy. In economically developed countries, hematological malignancies (blood cancers) are the fifth most prevalent cancer kind.
They're generally divided into three groups based on whether cancer starts in the blood (leukemia), lymph nodes (Hodgkin's lymphoma and non-Hodgkin's lymphoma), or bone (osteosarcomas and myelomas). The global hematologic malignancies testing market is undergoing a significant change about the advancements that have already taken place and are currently invading the market space.
Additionally, with the emergence of advanced diagnostic technologies, there is immense potential for emerging submarkets such as the nucleic acid extraction market to continue fueling the overall hematologic malignancies testing market. Further, with highly opportunistic trends coming into play with the rapid incorporation of hematologic malignancies testing in the management of cancer in healthcare settings, there is immense potential for growth in this market.
Market Segmentation
by Platform
- Polymerase Chain Reaction (PCR)
- Next-Generation Sequencing (NGS)
- Fluorescence In-Situ Hybridization (FISH)
- Flow Cytometry
- Immunohistochemistry (IHC)
- Other Platforms
by Disease
- Leukemia
- Lymphoma
- Multiple Myeloma
- Myeloproliferative Neoplasm
- Myelodysplastic Syndrome
by Product
- Kits
- Services
by End User
- Specialty Clinics and Hospitals
- Diagnostic Laboratories
- Reference Laboratories
- Research Institutions
Demand - Drivers and Limitations
Following are the demand drivers for the hematologic malignancies testing market:
- Increasing Key Player Initiatives
- Growing Funding in the Market for Hematologic Malignancies Testing
The market is expected to face some limitations too due to the following challenges:
- Lack of Qualified Professionals
- Issues Concerning the Analytical Validity of Cancer Genetic Testing
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.
Some prominent names established in this market are:
- Abbott.
- ASURAGEN, INC.
- Adaptive Biotechnologies
- ARUP Laboratories
- Bio-Rad Laboratories, Inc.
- F. Hoffmann-La Roche Ltd
- Illumina, Inc.
- ICON plc
- Invivoscribe, Inc.
- Invitae Corporation.
- Laboratory Corporation of America Holdings
- NeoGenomics Laboratories
- OHSU's Knight Diagnostic Laboratories
- Precipio
- QIAGEN N.V.
- Quest Diagnostics
- Sysmex Corporation
Key Topics Covered:
1 Market
2 Market Dynamics
2.1 Overview
2.2 Impact Analysis
2.3 Market Drivers
2.3.1 Rising Incidence in Hematologic Malignancies
2.3.1.1 New Cases
2.3.1.2 Deaths
2.3.2 Increasing Key Player Initiatives
2.3.3 Growing Funding in the Market for Hematologic Malignancies Testing
2.4 Market Restraints
2.4.1 Lack of Qualified Professionals
2.4.2 Issues Concerning the Analytical Validity of Cancer Genetic Testing
2.5 Market Opportunities
2.5.1 Increasing Research and Development Activities
2.5.2 Technological Advancements in the Field of Hematologic Malignancies Testing
2.6 Industry Analysis
2.7 COVID-19's Impact on Cancer Diagnostic Market
2.8 Supply Chain Analysis
2.8.1 Key Entities in Supply Chain
2.9 Pricing Analysis
3 Competitive Landscape
3.1 Overview
3.2 Synergistic Activities
3.3 Product Launches
3.4 Product Approvals
3.5 Mergers and Acquisitions
3.6 Other Business Activities
3.7 Market Share Analysis (by Company), 2020 and 2021
3.8 Growth-Share Analysis (by Platform)
4 Products
5 Platform
6 Diseases
7 End User
8 Region
For more information about this report visit https://www.researchandmarkets.com/r/eu87le
Attachment
